- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.03. | Transcode Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 23.02. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.02. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.02. | TransCode Therapeutics, Inc.: TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 | 437 | PR Newswire | BOSTON, Feb. 5, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics... ► Artikel lesen | |
| 06.01. | Transcode Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| TRANSCODE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 22.12.25 | TransCode Therapeutics appoints Jack E. Stover to board of directors | 2 | Investing.com | ||
| 22.12.25 | Transcode Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.12.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial | 266 | PR Newswire | BOSTON, Dec. 11, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate... ► Artikel lesen | |
| 11.12.25 | Transcode Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.11.25 | TransCode Therapeutics appoints Michel Janicot as development officer | 1 | Investing.com | ||
| 27.10.25 | Transcode Therapeutics ändert Bedingungen für Vorzugsaktien nach Aktionärszustimmung | 3 | Investing.com Deutsch | ||
| 27.10.25 | Transcode Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.10.25 | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.10.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO | 288 | PR Newswire | Safety primary endpoint achieved
Median treatment duration of 4 months with a range of 2 to 12 months and three patients remain on trial
RECIST data with... ► Artikel lesen | |
| 08.10.25 | TransCode Therapeutics Stock Jumps 21% On Polynoma Acquisition | 2 | RTTNews | ||
| 08.10.25 | TransCode Therapeutics stock soars after Polynoma acquisition | 3 | Investing.com | ||
| 08.10.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology ... | 275 | PR Newswire | TransCode acquires 100% of the issued and outstanding interests of Polynoma from CK Life Sciences
Concurrent equity investment of $25 Million from CK Life Sciences... ► Artikel lesen | |
| 08.05.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported | 359 | PR Newswire | 15 patients treated across four escalating dose levels of TTX-MC138
No significant safety or dose limiting toxicities reported
10 patients remain on study with... ► Artikel lesen | |
| 05.05.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split | 446 | PR Newswire | BOSTON, May 5, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more effectively... ► Artikel lesen | |
| 02.05.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces 1-for-28 Reverse Stock Split | 272 | PR Newswire | Split designed to achieve compliance with Nasdaq minimum bid price requirements
BOSTON, May 2, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ)... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,20 | +0,13 % | BioNTech überrascht: Krebsdaten geben Hoffnung! | BioNTech treibt den strategischen Wandel hin zu einem Onkologie-Unternehmen voran und erzielt dabei erste vielversprechende klinische Fortschritte, insbesondere im Bereich Lungenkrebs. Gleichzeitig... ► Artikel lesen | |
| QIAGEN | 35,310 | +1,17 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| NOVAVAX | 6,624 | -0,97 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 18,000 | 0,00 % | Morning Market Movers: Super Micro Computer, Bimergen Energy, Palatin Technologies, Intellicheck See Big Swings | HONG KONG (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| BRAIN BIOTECH | 2,410 | -0,41 % | EQS-News: BRAIN Biotech AG: BRAIN Biotech erhält bedeutendes Patent für seine CRISPR-BMC Genome-Editing-Technologie | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Patent
BRAIN Biotech erhält bedeutendes Patent für seine CRISPR-BMC Genome-Editing-Technologie
23.03.2026 / 11:05 CET/CEST
Für... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, INC. - 8-K, Current Report | ||
| INOVIO PHARMACEUTICALS | 0,950 | -2,56 % | Kapitalerhöhung mit Verwässerungseffekt: Inovio-Aktie stürzt ab | ||
| COSCIENS BIOPHARMA | 0,835 | +3,09 % | COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | TORONTO, ONTARIO, March 25, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on the development of natural... ► Artikel lesen | |
| XOMA ROYALTY | 28,600 | 0,00 % | XOMA Royalty Corporation: XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements | Portfolio receipts: • Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones, in full year 2025 • Total receipts increased 9% with royalties... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | ||
| PHIO PHARMACEUTICALS | 1,290 | -0,77 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762 | King of Prussia, Pennsylvania--(Newsfile Corp. - March 30, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| ORAGENICS | 0,580 | 0,00 % | ORAGENICS INC - 8-K, Current Report | ||
| VIVUS | - | - | VIVUS B.V.: VIVUS Reinforces QSIVA's Clinical Efficacy and Safety in Obesity Management | - QSIVA offers clinically meaningful weight loss supported by a well-established safety profile, now available at a reduced price across Nordics and Poland
AMSTERDAM, March 25, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| TENAX THERAPEUTICS | 12,300 | +6,03 % | Tenax Therapeutics, Inc.: Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial and opened long-term OLE study for patients... ► Artikel lesen | |
| BIOLINERX | 1,642 | 0,00 % | BioLineRx Ltd.: BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) | GLIX1, a TET2 activator, is a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers
GLIX1 has demonstrated potent... ► Artikel lesen |
Das Unternehmen TRANSCODE THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 8,580 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRANSCODE THERAPEUTICS INC finden Sie auf Wallstreet Online.